The clinical efficacy of existing cancer therapies is still far from satisfactory. There is an
urgent need to integrate the emerging biomedical discovery and technological innovation …

Adrenocortical carcinoma (ACC) is an aggressive and rare neoplasm that originates in the
cortex of the adrenal gland. The disease is associated with heterogeneous but mostly poor …

Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …

The current treatment strategies for cancer therapy have posed many problems in achieving
high efficacy. Therefore, an urgent step is needed to develop innovative therapies that can …

Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from
steroidogenic cells within the adrenal cortex. In this study, we have assessed for the …

Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1–2
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …

Background There has been widespread concern about the high cancer mortality rate and
the shortcomings of conventional cancer treatments. Immunotherapy is a novel oncology …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …

Adrenocortical tumors range from primary bilateral micronodular or macronodular forms of
adrenocortical disease to conventional adrenocortical adenomas and carcinomas. Accurate …

Adrenocortical carcinoma (ACC) is a rare, highly aggressive cancer, often insensitive to
conventional chemotherapeutics agents. Early diagnosis, followed by radical surgical …